M. Kaufmann, G. Von-minckwitz, H. D. Bear, A. Buzdar, P. Mcgale et al., Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives, Ann Oncol Off J Eur Soc Med Oncol, vol.18, pp.1927-1934, 2006.

J. Mieog, J. A. Van-der-hage, and C. Van-de-velde, Neoadjuvant chemotherapy for operable breast cancer, Br J Surg, vol.94, pp.1189-1200, 2007.

D. Mauri, N. Pavlidis, and J. Ioannidis, Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis, J Natl Cancer Inst, vol.97, pp.188-194, 2005.

C. Jackisch, N. Harbeck, J. Huober, G. Von-minckwitz, B. Gerber et al., Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus-Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts, Breast Care Basel Switz, vol.10, pp.211-219, 2015.

, Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials, Lancet Oncol, vol.19, issue.17, pp.30777-30782, 2018.

F. Penault-llorca and N. Radosevic-robin, Biomarkers of residual disease after neoadjuvant therapy for breast cancer, Nat Rev Clin Oncol, vol.13, pp.487-503, 2016.

P. Cortazar, L. Zhang, M. Untch, K. Mehta, J. P. Costantino et al., Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet Lond Engl, vol.384, pp.164-172, 2014.

G. Von-minckwitz, M. Untch, J. Blohmer, S. D. Costa, H. Eidtmann et al., Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, pp.1796-1804, 2012.

S. A. Patel and A. Demichele, Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data, Curr Oncol Rep, vol.19, p.28733827, 2017.

E. Thomas, F. A. Holmes, T. L. Smith, A. U. Buzdar, D. K. Frye et al., The use of alternate, noncross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.22, pp.2294-2302, 2004.

H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer, E. P. Mamounas et al., Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27, J Clin Oncol Off J Am Soc Clin Oncol, vol.24, pp.2019-2027, 2006.

M. Knauer, A. Haid, Y. Schneider, R. Kö-berle-wü-hrer, A. Lang et al., Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer, Eur J Surg Oncol EJSO, vol.35, pp.798-804, 2009.

A. M. Gonzalez-angulo, X. Lei, R. H. Alvarez, M. C. Green, J. L. Murray et al., Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer, Clin Breast Cancer, vol.15, pp.325-331, 2015.

. Minckwitz-g-von, M. Rezai, H. Tesch, J. Huober, B. Gerber et al., Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer-The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29), Eur J Cancer, vol.64, pp.12-21, 2016.

N. Masuda, Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy, New England Journal of Medicine, pp.2147-2159, 2017.

C. W. Elston and I. O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, pp.403-410, 1991.

A. J. Balaton, V. L. Doussal, L. Arnould, C. Barlier, J. P. Bellocq et al., Recommandations pour l'é valuation immunohistochimique des ré cepteurs hormonaux sur coupes en paraffine dans les carcinomes mammaires Mise à jour 1999. /data/revues/02426498/00190004/336, p.11, 2008.

A. Wolff, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer, Journal of Clinical Oncology, vol.1, pp.3997-4013, 2013.

E. Senkus, S. Kyriakides, S. Ohno, F. Penault-llorca, P. Poortmans et al., Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol, vol.26, issue.5, pp.8-30, 2015.

M. A. Bollet, L. Belin, F. Reyal, F. Campana, R. Dendale et al., Preoperative radio-chemotherapy in early breast cancer patients: long-term results of a phase II trial, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.102, pp.82-88, 2012.

V. Marchand, A. Angelergues, V. Gobaux, D. Hajage, Y. M. Kirova et al., Prospective and comparative evaluation of the toxicity of adjuvant concurrent chemoradiotherapy after neoadjuvant chemotherapy for breast cancer, Am J Clin Oncol, vol.36, pp.425-429, 2013.

M. M. Joffe and P. R. Rosenbaum, Invited commentary: propensity scores, Am J Epidemiol, vol.150, pp.327-333, 1999.

J. Labarère, J. Bosson, P. François, and M. J. Fine, Rev Med Interne, vol.29, pp.255-258, 2008.

M. A. Brookhart, S. Schneeweiss, K. J. Rothman, R. J. Glynn, J. Avorn et al., Variable selection for propensity score models, Am J Epidemiol, vol.163, pp.1149-1156, 2006.

R. A. Stone, D. S. Obrosky, D. E. Singer, W. N. Kapoor, and M. J. Fine, Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Pneumonia Patient Outcomes Research Team (PORT) Investigators, Med Care, vol.33, pp.56-66, 1995.

P. C. Austin, P. Grootendorst, and G. M. Anderson, A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study, Stat Med, vol.26, pp.734-753, 2007.

S. M. Perkins, W. Tu, M. G. Underhill, X. H. Zhou, and M. D. Murray, The use of propensity scores in pharmacoepidemiologic research, Pharmacoepidemiol Drug Saf, vol.9, pp.1099-1557, 2000.

M. Knauer, A. Haid, Y. Schneider, R. Kö-berle-wü-hrer, A. Lang et al., Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer, Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol, vol.35, pp.798-804, 2009.

, Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04) | Cancer Research, 2019.

D. A. Berry, C. Cirrincione, I. C. Henderson, M. L. Citron, D. R. Budman et al., Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer, JAMA, vol.295, pp.1658-1667, 2006.

G. Chen, Z. Guo, M. Liu, G. Yao, J. Dong et al., Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials, Oncol Res, vol.25, pp.1567-1578, 2017.

A. Lluch, M. Ruiz-borrego, C. H. Barrios, J. Bines, L. Torrecillas et al., 422 Final Safety Data From a Randomised Phase III Trial (CIBOMA/2004-01_GEICAM/2003-11) Assessing Adjuvant Capecitabine Maintenance Therapy After Standard Chemotherapy for Triple-negative Early Breast Cancer. a Study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Español De Investigacion En Cancer De Mama (GEICAM), Eur J Cancer, vol.48, pp.169-170, 2012.

G. Von-minckwitz, C. Huang, M. S. Mano, S. Loibl, E. P. Mamounas et al., Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer, N Engl J Med, vol.380, pp.617-628, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02464524

, Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer-Full Text View-Clinical-Trials.gov, p.15, 2019.